Trials / Completed
CompletedNCT02278952
Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional cohort study to assess a novel assay to detect excessive or insufficient immunosuppression from the drug tacrolimus in lung transplant recipients. The assay measures mean residual expression (MRE) of genes downstream of nuclear factor of activated T cells (NFAT), a transcription factor regulated by tacrolimus. The investigators will assess whether MRE levels identify subjects at risk for rejection (insufficient immunosuppression) or infection (excessive immunosuppression).
Conditions
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2017-05-01
- Completion
- 2018-01-01
- First posted
- 2014-10-30
- Last updated
- 2019-12-03
- Results posted
- 2019-12-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02278952. Inclusion in this directory is not an endorsement.